Neogen Posts Fifth Straight Quarter of Core Growth as Petrifilm Transition Hits Key Derisking Milestone
Fiscal first-quarter 2027 results, reported October 6, 2026
Neogen delivered a stronger-than-expected start to fiscal 2027, with first-quarter revenue of $222.8 million and core growth of 8.1%, prompting management to raise full-year revenue guidance to a range of $885 million to $890 million and adjusted EBITDA guidance to $181 million to $183 million. The print marks the fifth consecutive quarter of core growth for a company that spent much of the past two years working through supply chain dysfunction and commercial underperformance following its merger with 3M's Food Safety business. CEO Mikhael Nassif framed the quarter as evidence that the turnaround is "gaining momentum," though he was careful to temper enthusiasm, noting "there's more work ahead, but the foundation is getting stronger."
Investors should note that roughly 300 basis points of the quarter's growth was inorganic in nature, reflecting order timing that pulled forward demand from the second quarter and an easy comparison against distributor inventory adjustments that had depressed the year-ago period. CFO Bryan Riggsbee was transparent about this, telling analysts the company believes "looking at the first half in total is most reflective of the current trajectory of the business," guiding to roughly 3.5% core growth across the first two quarters combined. That framing suggests the second quarter will look soft in isolation, a dynamic investors should model carefully rather than extrapolate the Q1 beat.
Petrifilm Manufacturing Transfer Clears First Major Hurdle
The most consequential operational update was confirmation that Neogen has achieved full validation of its first Petrifilm SKU as it prepares to begin transferring manufacturing from its transition partner to its own Lansing, Michigan facility next month. Full validation means the product has completed production, quality, and stability testing and has demonstrated equivalent performance to the incumbent-manufactured product — a milestone Nassif called "a major derisking milestone for the program." This is the final piece of integrating the legacy 3M Food Safety business, and management laid out four gating criteria it will track SKU-by-SKU across the multi-quarter transfer of all 17 products: customer continuity, safety stock management, new supplier onboarding, and disciplined sequencing.
Riggsbee gave investors a clearer timeline on when the transition will actually pay off financially. Duplicative costs tied to running parallel manufacturing are expected to peak and then subside as the transfer completes through fiscal 2028, with the operational efficiencies identified during the process beginning to show up as margin improvement of 200 to 300 basis points in fiscal 2029, fully realized the following year. That is a multi-year payoff window investors will need patience for, even as the near-term derisking reduces tail risk around Petrifilm, a product line management has repeatedly emphasized is not FDA-regulated — the company disclosed that FDA-regulated products totaled less than $10 million of fiscal 2026 sales, almost entirely in Animal Safety.
New Hyperspectral Imaging Partnership Signals Innovation Pivot
Neogen announced a strategic collaboration with Hinalea, an early leader in hyperspectral imaging technology, as part of its push to rebuild what Nassif called the company's "innovation engine." The technical distinction matters for understanding the opportunity: a standard camera captures three bands of light — red, green, and blue — while a hyperspectral sensor can capture 100 or more bands, building what Nassif described as "a detailed fingerprint of every pixel of an image." Applied to food safety testing, the technology could allow earlier detection of contamination and simplify the downstream testing workflows customers currently rely on. Management characterized this as the first of what it expects to be several technology partnerships and licensing arrangements as it pursues what Nassif called "elevating global food safety testing at the point of processing to enable automation and faster decision-making." Further detail on the innovation pipeline and the company's broader R&D strategy is expected at an Investor Day held the following day, where executives also planned to demonstrate a live hyperspectral camera.
Segment Performance: Both Food Safety and Animal Safety Accelerate
Food Safety, Neogen's larger segment, generated $163.2 million in revenue, up 8.1% on a core basis, though roughly 400 basis points of that reflected the order-timing and prior-year comparison benefits. Indicator testing and culture media products, including Petrifilm, grew 11%, while bacterial and general sanitation products grew 7%, with pathogen detection up double digits. Animal Safety revenue reached $59.6 million, up 8% on a core basis, with strength in veterinary instruments — particularly needles and syringes benefiting from improved supply — and biosecurity products driven by insect control. Management pointed to USDA data showing U.S. herd sizes at multi-decade lows with favorable pricing supporting anticipated herd rebuilding, a tailwind for Animal Safety demand looking forward. Chief Commercial Officer Joe Freels highlighted early traction from a reorganized global strategic accounts model, under which the company moved from fragmented regional or category-based sales coverage to single accountable owners for major multinational customers. He cited 6.2% growth in that account base during the quarter, putting it on pace to exceed 8% for the full year, and credited newly implemented weekly sales KPI reviews with giving the organization "visibility and transparency...in real time" to course-correct faster than in the past.
Margins Expand in Q1 But Full-Year Expansion Remains Back-Half Loaded
Adjusted EBITDA margin expanded 170 basis points year-over-year to 18.7% in the quarter, but management was direct in clarifying that the first half of fiscal 2027 overall will look similar to the first quarter, implying a softer second quarter margin than the Q1 print suggests. Riggsbee confirmed that full-year margin expansion guidance remains roughly consistent with fiscal 2026 levels, with investments in commercial infrastructure, R&D, and a national sales meeting weighing on the first half before inventory write-off reductions and sample collection efficiencies — improvements the company says are already showing results — provide a tailwind in the back half. Free cash flow of $4.7 million represented a $18 million improvement year-over-year, aided by both higher operating cash flow and lower capital expenditures as the company moves past the heaviest capital-intensive phase of the Petrifilm transition.
Balance Sheet: Debt Paydown Continues Ahead of Genomics Sale
Neogen ended the quarter with approximately $774 million of debt and $172 million of cash, having made voluntary term loan paydowns of $20 million in June and $10 million in September. The pending divestiture of its genomics business remains under regulatory review in Australia and New Zealand, with a final decision expected by the end of December. Management reiterated it intends to apply the expected roughly $140 million in net proceeds primarily toward debt reduction, which it believes would bring net leverage below 3 times at closing and closer to 2.5 times by fiscal year-end — a meaningful deleveraging path for a company that has spent the past several quarters working to restore balance sheet credibility alongside operational credibility.